# Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

Source: https://onco.cc/trials/nct05037279/  
OnCo record `nct05037279` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bacillus Calmette-Guerin: Strain Russian BCG-I in bladder & urothelial cancer, run by Verity Pharmaceuticals Inc., now recruiting.

## Summary

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) is a phase 3 interventional study registered as NCT05037279 by Verity Pharmaceuticals Inc., with 540 participants planned, started 2024-04-24 and due to reach its primary completion in 2029-02. Interventions recorded: Bacillus Calmette-Guerin: Strain Russian BCG-I and Bacillus Calmette-Guerin: Strain TICE.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05037279
- Phase: 3
- Setting: A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.
- Sponsor: Verity Pharmaceuticals Inc.
- Enrolled: 540

## Sources

- ClinicalTrials.gov NCT05037279: https://clinicaltrials.gov/study/NCT05037279

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [Verity Pharmaceuticals](https://onco.cc/companies/verity-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05037279.json